ETFChannel.com
HZNP Description — Horizon Therapeutics Plc

Horizon Therapeutics is focused on researching, developing and commercializing medicines that address the needs for people with rare and rheumatic diseases. Co. has two segments, the orphan segment and the inflammation segment. The Orphan segment includes: TEPEZZA, which is indicated for the treatment of thyroid eye diseas; KRYSTEXXA, which is indicated for the treatment of uncontrolled gout; and PROCYSBI, which is indicated for nephropathic cystinosis. The Inflammation segment includes: PENNSAID 2% w/w, which is indicated for the treatment of pain of osteoarthritis (OA), of the knee(s); and DUEXIS, which is indicated for the relief of signs and symptoms of rheumatoid arthritis and OA.

Company Name: 
Horizon Therapeutics Plc
Website: 
www.horizontherapeutics.com
Sector: 
Biotechnology
Number of ETFs Holding HZNP: 
59
Total Market Value Held by ETFs: 
$2,968,524,149.92
Total Market Capitalization: 
$25,030,000,000
% of Market Cap. Held by ETFs: 
11.86%
 ETF   HZNP Weight   HZNP Amount 
 VTI   0.06%   $758,027,059         
 VO   0.38%   $580,236,031         
 VXF   0.37%   $339,479,809         
 USMV   0.75%   $231,466,396         
 VUG   0.14%   $210,357,984         
 VOT   0.81%   $169,963,694         
 XBI   0.98%   $84,335,773         
 VHT   0.41%   $83,382,443         
 IWP   0.61%   $77,689,736         
 IWF   0.12%   $73,831,879         
List of all 59 ETFs holding HZNP »
Quotes delayed 20 minutes

Email EnvelopeFree HZNP Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (2.55 out of 4)
6th percentile
(ranked lower than approx. 94% of all stocks covered)

Analysts Forecast:
HZNP Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding HZNP | Horizon Therapeutics Plc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.